{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:11:45Z","timestamp":1788599505547,"version":"build-2803163510"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12705-x","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:21:31Z","timestamp":1788596491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advancements in NRF2-regulated ferroptosis modulation for targeted cancer therapy"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8549-2993","authenticated-orcid":false,"given":"Ozge Cemiloglu","family":"Ulker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-7731","authenticated-orcid":false,"given":"Antonella","family":"Capozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1646-7799","authenticated-orcid":false,"given":"Nisa Nur","family":"Sari-Goktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3534-1502","authenticated-orcid":false,"given":"Maurizio","family":"Sorice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-8706","authenticated-orcid":false,"given":"Luciano","family":"Saso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-4106","authenticated-orcid":false,"given":"Brigitta","family":"Buttari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"12705_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ccr.2006.08.015","volume":"10","author":"PT Schumacker","year":"2006","unstructured":"Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10:175\u2013176. https:\/\/doi.org\/10.1016\/j.ccr.2006.08.015","journal-title":"Cancer Cell"},{"key":"12705_CR2","doi-asserted-by":"publisher","first-page":"10823","DOI":"10.1158\/0008-5472.CAN-07-0783","volume":"67","author":"C Xia","year":"2007","unstructured":"Xia C, Meng Q, Liu L-Z et al (2007) Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 67:10823\u201310830. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0783","journal-title":"Cancer Res"},{"key":"12705_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/antiox10050642","volume":"10","author":"S Arfin","year":"2021","unstructured":"Arfin S, Jha NK, Jha SK et al (2021) Oxidative Stress in Cancer Cell Metabolism. Antioxid (Basel) 10:642. https:\/\/doi.org\/10.3390\/antiox10050642","journal-title":"Antioxid (Basel)"},{"key":"12705_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbapap.2009.11.005","volume":"1804","author":"IA Abreu","year":"2010","unstructured":"Abreu IA, Cabelli DE (2010) Superoxide dismutases-a review of the metal-associated mechanistic variations. Biochim Biophys Acta 1804:263\u2013274. https:\/\/doi.org\/10.1016\/j.bbapap.2009.11.005","journal-title":"Biochim Biophys Acta"},{"key":"12705_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers10090305","volume":"10","author":"N Chandimali","year":"2018","unstructured":"Chandimali N, Jeong DK, Kwon T (2018) Peroxiredoxin II Regulates Cancer Stem Cells and Stemness-Associated Properties of Cancers. Cancers (Basel) 10:305. https:\/\/doi.org\/10.3390\/cancers10090305","journal-title":"Cancers (Basel)"},{"issue":"2001091","key":"12705_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/1615-9861","volume":"1","author":"T Rabilloud","year":"2001","unstructured":"Rabilloud T, Heller M, Rigobello MP et al (2001) The mitochondrial antioxidant defence system and its response to oxidative stress. Proteomics 1(2001091):1105\u20131110. https:\/\/doi.org\/10.1002\/1615-9861. :9%3C1105::AID-PROT1105%3E3.0.CO;2-M","journal-title":"Proteomics"},{"key":"12705_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbalip.2008.03.010","volume":"1781","author":"A Cipak","year":"2008","unstructured":"Cipak A, Jaganjac M, Tehlivets O et al (2008) Adaptation to oxidative stress induced by polyunsaturated fatty acids in yeast. Biochim Biophys Acta 1781:283\u2013287. https:\/\/doi.org\/10.1016\/j.bbalip.2008.03.010","journal-title":"Biochim Biophys Acta"},{"key":"12705_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/antiox6030051","volume":"6","author":"F Ahmadinejad","year":"2017","unstructured":"Ahmadinejad F, Geir M\u00f8ller S, Hashemzadeh-Chaleshtori M et al (2017) Molecular Mechanisms behind Free Radical Scavengers Function against Oxidative Stress. Antioxid (Basel) 6:51. https:\/\/doi.org\/10.3390\/antiox6030051","journal-title":"Antioxid (Basel)"},{"key":"12705_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","volume":"98","author":"M Yamamoto","year":"2018","unstructured":"Yamamoto M, Kensler TW, Motohashi H (2018) The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev 98:1169\u20131203. https:\/\/doi.org\/10.1152\/physrev.00023.2017","journal-title":"Physiol Rev"},{"key":"12705_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.redox.2015.06.019","volume":"6","author":"L-O Klotz","year":"2015","unstructured":"Klotz LO, S\u00e1nchez-Ramos C, Prieto-Arroyo I et al (2015) Redox regulation of FoxO transcription factors. Redox Biol 6:51\u201372. https:\/\/doi.org\/10.1016\/j.redox.2015.06.019","journal-title":"Redox Biol"},{"key":"12705_CR11","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1038\/srep03793","volume":"4","author":"T Zhao","year":"2014","unstructured":"Zhao T, Zhu Y, Morinibu A et al (2014) HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Sci Rep 4:3793. https:\/\/doi.org\/10.1038\/srep03793","journal-title":"Sci Rep"},{"key":"12705_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ncb1676","volume":"10","author":"J-Y Yang","year":"2008","unstructured":"Yang JY, Zong CS, Xia W et al (2008) ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10:138\u2013148. https:\/\/doi.org\/10.1038\/ncb1676","journal-title":"Nat Cell Biol"},{"key":"12705_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M de la Rojo","year":"2018","unstructured":"de la Rojo M, Chapman E, Zhang DD (2018) NRF2 and the Hallmarks of Cancer. Cancer Cell 34:21\u201343. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.022","journal-title":"Cancer Cell"},{"key":"12705_CR14","doi-asserted-by":"publisher","first-page":"101107","DOI":"10.1016\/j.redox.2019.101107","volume":"23","author":"M Dodson","year":"2019","unstructured":"Dodson M, Castro-Portuguez R, Zhang DD (2019) NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol 23:101107. https:\/\/doi.org\/10.1016\/j.redox.2019.101107","journal-title":"Redox Biol"},{"key":"12705_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060\u20131072. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042","journal-title":"Cell"},{"key":"12705_CR16","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1038\/oncsis.2017.65","volume":"6","author":"Z Fan","year":"2017","unstructured":"Fan Z, Wirth A-K, Chen D et al (2017) Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis 6:e371. https:\/\/doi.org\/10.1038\/oncsis.2017.65","journal-title":"Oncogenesis"},{"key":"12705_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.canlet.2017.12.025","volume":"416","author":"L-C Chang","year":"2018","unstructured":"Chang LC, Chiang SK, Chen SE et al (2018) Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Lett 416:124\u2013137. https:\/\/doi.org\/10.1016\/j.canlet.2017.12.025","journal-title":"Cancer Lett"},{"key":"12705_CR18","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.3390\/ijms23105709","volume":"23","author":"V Consoli","year":"2022","unstructured":"Consoli V, Sorrenti V, Pittal\u00e0 V et al (2022) Heme Oxygenase Modulation Drives Ferroptosis in TNBC Cells. Int J Mol Sci 23:5709. https:\/\/doi.org\/10.3390\/ijms23105709","journal-title":"Int J Mol Sci"},{"key":"12705_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41419-024-06948-4","volume":"15","author":"T Zhong","year":"2024","unstructured":"Zhong T, Li Y, Jin M et al (2024) Downregulation of 4-HNE and FOXO4 collaboratively promotes NSCLC cell migration and tumor growth. Cell Death Dis 15:546. https:\/\/doi.org\/10.1038\/s41419-024-06948-4","journal-title":"Cell Death Dis"},{"key":"12705_CR20","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.3390\/molecules25225474","volume":"25","author":"S Saha","year":"2020","unstructured":"Saha S, Buttari B, Panieri E et al (2020) An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation. Molecules 25:5474. https:\/\/doi.org\/10.3390\/molecules25225474","journal-title":"Molecules"},{"key":"12705_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1089\/ars.2023.0398","volume":"40","author":"JW Kupiec-Weglinski","year":"2024","unstructured":"Kupiec-Weglinski JW (2024) NRF2: New Mechanistic Insights and Therapeutic Perspectives. Antioxid Redox Signal 40:632\u2013635. https:\/\/doi.org\/10.1089\/ars.2023.0398","journal-title":"Antioxid Redox Signal"},{"key":"12705_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.28251","volume":"63","author":"X Sun","year":"2016","unstructured":"Sun X, Ou Z, Chen R et al (2016) Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63:173\u2013184. https:\/\/doi.org\/10.1002\/hep.28251","journal-title":"Hepatology"},{"key":"12705_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.14348\/molcells.2023.0005","volume":"46","author":"A Shakya","year":"2023","unstructured":"Shakya A, McKee NW, Dodson M et al (2023) Anti-Ferroptotic Effects of Nrf2: Beyond the Antioxidant Response. Mol Cells 46:165\u2013175. https:\/\/doi.org\/10.14348\/molcells.2023.0005","journal-title":"Mol Cells"},{"key":"12705_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41420-023-01753-y","volume":"9","author":"J Wang","year":"2023","unstructured":"Wang J, Wu N, Peng M et al (2023) Ferritinophagy: research advance and clinical significance in cancers. Cell Death Discov 9:463. https:\/\/doi.org\/10.1038\/s41420-023-01753-y","journal-title":"Cell Death Discov"},{"key":"12705_CR25","doi-asserted-by":"publisher","first-page":"1545339","DOI":"10.3389\/fimmu.2025.1545339","volume":"16","author":"D Sun","year":"2025","unstructured":"Sun D, Wang L, Wu Y et al (2025) Lipid metabolism in ferroptosis: mechanistic insights and therapeutic potential. Front Immunol 16:1545339. https:\/\/doi.org\/10.3389\/fimmu.2025.1545339","journal-title":"Front Immunol"},{"key":"12705_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2025.15393","volume":"31","author":"Q Yu","year":"2025","unstructured":"Yu Q, Ren L, Ren F, Li F (2025) Oxidative stress as a nexus: Integrating mitophagy and ferroptosis in endometrial carcinogenesis (Review). Oncol Lett 31:1\u201313. https:\/\/doi.org\/10.3892\/ol.2025.15393","journal-title":"Oncol Lett"},{"key":"12705_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.tibs.2008.12.008","volume":"34","author":"JD Hayes","year":"2009","unstructured":"Hayes JD, McMahon M (2009) NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34:176\u2013188. https:\/\/doi.org\/10.1016\/j.tibs.2008.12.008","journal-title":"Trends Biochem Sci"},{"key":"12705_CR28","doi-asserted-by":"publisher","first-page":"12846","DOI":"10.1038\/s41598-018-31281-0","volume":"8","author":"MJ Kerins","year":"2018","unstructured":"Kerins MJ, Ooi A (2018) A catalogue of somatic NRF2 gain-of-function mutations in cancer. Sci Rep 8:12846. https:\/\/doi.org\/10.1038\/s41598-018-31281-0","journal-title":"Sci Rep"},{"key":"12705_CR29","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/cam4.2101","volume":"8","author":"S Wu","year":"2019","unstructured":"Wu S, Lu H, Bai Y (2019) Nrf2 in cancers: A double-edged sword. Cancer Med 8:2252\u20132267. https:\/\/doi.org\/10.1002\/cam4.2101","journal-title":"Cancer Med"},{"key":"12705_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/cancers13010046","volume":"13","author":"K Taguchi","year":"2020","unstructured":"Taguchi K, Yamamoto M (2020) The KEAP1-NRF2 System as a Molecular Target of Cancer Treatment. Cancers (Basel) 13:46. https:\/\/doi.org\/10.3390\/cancers13010046","journal-title":"Cancers (Basel)"},{"key":"12705_CR31","doi-asserted-by":"publisher","first-page":"166788","DOI":"10.1016\/j.bbadis.2023.166788","volume":"1869","author":"J Lee","year":"2023","unstructured":"Lee J, Roh J-L (2023) Targeting Nrf2 for ferroptosis-based therapy: Implications for overcoming ferroptosis evasion and therapy resistance in cancer. Biochim Biophys Acta Mol Basis Dis 1869:166788. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166788","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"12705_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3892\/mmr.2022.12904","volume":"27","author":"X Wu","year":"2023","unstructured":"Wu X, Chen S, Huang K, Lin G (2023) Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. Mol Med Rep 27:17. https:\/\/doi.org\/10.3892\/mmr.2022.12904","journal-title":"Mol Med Rep"},{"key":"12705_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-023-00411-4","volume":"12","author":"X Liu","year":"2023","unstructured":"Liu X, Zhong S, Qiu K et al (2023) Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis. Exp Hematol Oncol 12:47. https:\/\/doi.org\/10.1186\/s40164-023-00411-4","journal-title":"Exp Hematol Oncol"},{"key":"12705_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41420-025-02564-z","volume":"11","author":"L Zuo","year":"2025","unstructured":"Zuo L, Zou X, Ge J et al (2025) The Nrf2-HMOX1 pathway as a therapeutic target for reversing cisplatin resistance in non-small cell lung cancer via inhibiting ferroptosis. Cell Death Discov 11:287. https:\/\/doi.org\/10.1038\/s41420-025-02564-z","journal-title":"Cell Death Discov"},{"key":"12705_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12967-021-03042-7","volume":"19","author":"L Feng","year":"2021","unstructured":"Feng L, Zhao K, Sun L et al (2021) SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis. J Transl Med 19:367. https:\/\/doi.org\/10.1186\/s12967-021-03042-7","journal-title":"J Transl Med"},{"key":"12705_CR36","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.3390\/cancers17162714","volume":"17","author":"T Tahsin","year":"2025","unstructured":"Tahsin T, McPhail DK, Champion JD et al (2025) Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer Cells. Cancers (Basel) 17:2714. https:\/\/doi.org\/10.3390\/cancers17162714","journal-title":"Cancers (Basel)"},{"key":"12705_CR37","doi-asserted-by":"publisher","first-page":"e1904197","DOI":"10.1002\/adma.201904197","volume":"31","author":"C Liang","year":"2019","unstructured":"Liang C, Zhang X, Yang M, Dong X (2019) Recent Progress in Ferroptosis Inducers for Cancer Therapy. Adv Mater 31:e1904197. https:\/\/doi.org\/10.1002\/adma.201904197","journal-title":"Adv Mater"},{"key":"12705_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021) Broadening horizons: the role of ferroptosis in cancer. Nat Reviews Clin Oncol 18:280\u2013296. https:\/\/doi.org\/10.1038\/s41571-020-00462-0","journal-title":"Nat Reviews Clin Oncol"},{"key":"12705_CR39","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1073\/pnas.1014275108","volume":"108","author":"D Ren","year":"2011","unstructured":"Ren D, Villeneuve NF, Jiang T et al (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci 108:1433\u20131438. https:\/\/doi.org\/10.1073\/pnas.1014275108","journal-title":"Proc Natl Acad Sci"},{"key":"12705_CR40","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh A, Venkannagari S, Oh KH et al (2016) Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol 11:3214\u20133225. https:\/\/doi.org\/10.1021\/acschembio.6b00651","journal-title":"ACS Chem Biol"},{"key":"12705_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","volume":"41","author":"Q Cui","year":"2018","unstructured":"Cui Q, Wang J-Q, Assaraf YG et al (2018) Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat 41:1\u201325. https:\/\/doi.org\/10.1016\/j.drup.2018.11.001","journal-title":"Drug Resist Updat"},{"key":"12705_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME et al (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317\u2013331. https:\/\/doi.org\/10.1016\/j.cell.2013.12.010","journal-title":"Cell"},{"key":"12705_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1021\/acscentsci.7b00589","volume":"4","author":"R Shah","year":"2018","unstructured":"Shah R, Shchepinov MS, Pratt DA (2018) Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis. ACS Cent Sci 4:387\u2013396. https:\/\/doi.org\/10.1021\/acscentsci.7b00589","journal-title":"ACS Cent Sci"},{"key":"12705_CR44","doi-asserted-by":"publisher","first-page":"1458143","DOI":"10.1155\/2022\/1458143","volume":"2022","author":"Y Hu","year":"2022","unstructured":"Hu Y, Guo N, Yang T et al (2022) The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer. Oxid Med Cell Longev 2022:1458143. https:\/\/doi.org\/10.1155\/2022\/1458143","journal-title":"Oxid Med Cell Longev"},{"key":"12705_CR45","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1111\/jcmm.14511","volume":"23","author":"T Xu","year":"2019","unstructured":"Xu T, Ding W, Ji X et al (2019) Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med 23:4900\u20134912. https:\/\/doi.org\/10.1111\/jcmm.14511","journal-title":"J Cell Mol Med"},{"key":"12705_CR46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12:599\u2013620. https:\/\/doi.org\/10.1007\/s13238-020-00789-5","journal-title":"Protein Cell"},{"key":"12705_CR47","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3390\/cells10092401","volume":"10","author":"S-K Chiang","year":"2021","unstructured":"Chiang S-K, Chen S-E, Chang L-C (2021) The Role of HO-1 and Its Crosstalk with Oxidative Stress in Cancer Cell Survival. Cells 10:2401. https:\/\/doi.org\/10.3390\/cells10092401","journal-title":"Cells"},{"key":"12705_CR48","doi-asserted-by":"publisher","first-page":"114584","DOI":"10.1016\/j.bcp.2021.114584","volume":"190","author":"G Xu","year":"2021","unstructured":"Xu G, Wang H, Li X et al (2021) Recent progress on targeting ferroptosis for cancer therapy. Biochem Pharmacol 190:114584. https:\/\/doi.org\/10.1016\/j.bcp.2021.114584","journal-title":"Biochem Pharmacol"},{"key":"12705_CR49","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1080\/15548627.2016.1208889","volume":"12","author":"M Pajares","year":"2016","unstructured":"Pajares M, Jim\u00e9nez-Moreno N, Garc\u00eda-Yag\u00fce \u00c1J et al (2016) Transcription factor NFE2L2\/NRF2 is a regulator of macroautophagy genes. Autophagy 12:1902\u20131916. https:\/\/doi.org\/10.1080\/15548627.2016.1208889","journal-title":"Autophagy"},{"key":"12705_CR50","doi-asserted-by":"publisher","first-page":"1129662","DOI":"10.3389\/fphar.2023.1129662","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Peng X, Cen S et al (2023) Wogonin induces ferroptosis in pancreatic cancer cells by inhibiting the Nrf2\/GPX4 axis. Front Pharmacol 14:1129662. https:\/\/doi.org\/10.3389\/fphar.2023.1129662","journal-title":"Front Pharmacol"},{"key":"12705_CR51","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1002\/ptr.8258","volume":"38","author":"T Ming","year":"2024","unstructured":"Ming T, Lei J, Peng Y et al (2024) Curcumin suppresses colorectal cancer by induction of ferroptosis via regulation of p53 and solute carrier family 7 member 11\/glutathione\/glutathione peroxidase 4 signaling axis. Phytother Res 38:3954\u20133972. https:\/\/doi.org\/10.1002\/ptr.8258","journal-title":"Phytother Res"},{"key":"12705_CR52","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1002\/ptr.8328","volume":"38","author":"W Gao","year":"2024","unstructured":"Gao W, Li Y, Lin X et al (2024) Procyanidin B1 Promotes PSMC3-NRF2 Ubiquitination to Induce Ferroptosis in Glioblastoma. Phytother Res 38:5583\u20135597. https:\/\/doi.org\/10.1002\/ptr.8328","journal-title":"Phytother Res"},{"key":"12705_CR53","doi-asserted-by":"publisher","first-page":"176839","DOI":"10.1016\/j.ejphar.2024.176839","volume":"979","author":"X-F Bai","year":"2024","unstructured":"Bai XF, Hu J, Wang MF et al (2024) Cepharanthine triggers ferroptosis through inhibition of NRF2 for robust ER stress against lung cancer. Eur J Pharmacol 979:176839. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176839","journal-title":"Eur J Pharmacol"},{"key":"12705_CR54","doi-asserted-by":"publisher","first-page":"118139","DOI":"10.1016\/j.jep.2024.118139","volume":"328","author":"X Ji","year":"2024","unstructured":"Ji X, Chen Z, Lin W et al (2024) Esculin induces endoplasmic reticulum stress and drives apoptosis and ferroptosis in colorectal cancer via PERK regulating eIF2\u03b1\/CHOP and Nrf2\/HO-1 cascades. J Ethnopharmacol 328:118139. https:\/\/doi.org\/10.1016\/j.jep.2024.118139","journal-title":"J Ethnopharmacol"},{"key":"12705_CR55","doi-asserted-by":"publisher","first-page":"111312","DOI":"10.1016\/j.cbi.2024.111312","volume":"405","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Cai X, Ma X et al (2025) Delavinone elicits oxidative stress and triggers ferroptosis in colorectal cancer by inhibiting PKC\u03b4-mediated phosphorylation of Nrf2. Chem Biol Interact 405:111312. https:\/\/doi.org\/10.1016\/j.cbi.2024.111312","journal-title":"Chem Biol Interact"},{"key":"12705_CR56","doi-asserted-by":"publisher","first-page":"153370","DOI":"10.1016\/j.phymed.2020.153370","volume":"80","author":"J-S Lou","year":"2021","unstructured":"Lou J-S, Zhao L-P, Huang Z-H et al (2021) Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2\/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine 80:153370. https:\/\/doi.org\/10.1016\/j.phymed.2020.153370","journal-title":"Phytomedicine"},{"key":"12705_CR57","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/md22080357","volume":"22","author":"G Zhao","year":"2024","unstructured":"Zhao G, Liu Y, Wei X et al (2024) Identification of Penexanthone A as a Novel Chemosensitizer to Induce Ferroptosis by Targeting Nrf2 in Human Colorectal Cancer Cells. Mar Drugs 22:357. https:\/\/doi.org\/10.3390\/md22080357","journal-title":"Mar Drugs"},{"key":"12705_CR58","doi-asserted-by":"publisher","first-page":"114053","DOI":"10.1016\/j.yexcr.2024.114053","volume":"438","author":"X Yu","year":"2024","unstructured":"Yu X, He Z, Wang Z et al (2024) Brusatol hinders the progression of bladder cancer by Chac1\/Nrf2\/SLC7A11 pathway. Exp Cell Res 438:114053. https:\/\/doi.org\/10.1016\/j.yexcr.2024.114053","journal-title":"Exp Cell Res"},{"key":"12705_CR59","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.7150\/jca.96608","volume":"15","author":"W-L Duan","year":"2024","unstructured":"Duan WL, Wang XJ, Guo A et al (2024) miR-141-3p promotes paclitaxel resistance by attenuating ferroptosis via the Keap1-Nrf2 signaling pathway in breast cancer. J Cancer 15:5622\u20135635. https:\/\/doi.org\/10.7150\/jca.96608","journal-title":"J Cancer"},{"key":"12705_CR60","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/cas.13380","volume":"108","author":"R Shintoku","year":"2017","unstructured":"Shintoku R, Takigawa Y, Yamada K et al (2017) Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. Cancer Sci 108:2187\u20132194. https:\/\/doi.org\/10.1111\/cas.13380","journal-title":"Cancer Sci"},{"key":"12705_CR61","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.freeradbiomed.2018.10.426","volume":"129","author":"D Shin","year":"2018","unstructured":"Shin D, Kim EH, Lee J, Roh J-L (2018) Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med 129:454\u2013462. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.10.426","journal-title":"Free Radic Biol Med"},{"key":"12705_CR62","doi-asserted-by":"publisher","first-page":"110262","DOI":"10.1016\/j.cbi.2022.110262","volume":"369","author":"S Cai","year":"2023","unstructured":"Cai S, Ding Z, Liu X, Zeng J (2023) Trabectedin induces ferroptosis via regulation of HIF-1\u03b1\/IRP1\/TFR1 and Keap1\/Nrf2\/GPX4 axis in non-small cell lung cancer cells. Chem Biol Interact 369:110262. https:\/\/doi.org\/10.1016\/j.cbi.2022.110262","journal-title":"Chem Biol Interact"},{"key":"12705_CR63","doi-asserted-by":"publisher","first-page":"15098","DOI":"10.1021\/acs.jmedchem.4c00729","volume":"67","author":"M Liu","year":"2024","unstructured":"Liu M, Gao S, Wang Y et al (2024) Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. J Med Chem 67:15098\u201315117. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00729","journal-title":"J Med Chem"},{"key":"12705_CR64","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2022.05.017","volume":"187","author":"H Panda","year":"2022","unstructured":"Panda H, Suzuki M, Naito M et al (2022) Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity. Free Radic Biol Med 187:92\u2013104. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.05.017","journal-title":"Free Radic Biol Med"},{"key":"12705_CR65","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/OTT.S254995","volume":"13","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Li Y, Zhang R et al (2020) The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. Onco Targets Ther 13:5429\u20135441. https:\/\/doi.org\/10.2147\/OTT.S254995","journal-title":"Onco Targets Ther"},{"key":"12705_CR66","doi-asserted-by":"publisher","first-page":"102122","DOI":"10.1016\/j.redox.2021.102122","volume":"46","author":"X Ren","year":"2021","unstructured":"Ren X, Li Y, Zhou Y et al (2021) Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram\/copper-induced ferroptosis. Redox Biol 46:102122. https:\/\/doi.org\/10.1016\/j.redox.2021.102122","journal-title":"Redox Biol"},{"key":"12705_CR67","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/biomedicines11071798","volume":"11","author":"K-Y Tsai","year":"2023","unstructured":"Tsai KY, Wei PL, Lee CC et al (2023) 2,3,5,4\u2019-Tetrahydroxystilbene (TG1), a Novel Compound Derived from 2,3,5,4\u2019-Tetrahydroxystilbene-2-O-\u03b2-D-glucoside (THSG), Inhibits Colorectal Cancer Progression by Inducing Ferroptosis, Apoptosis, and Autophagy. Biomedicines 11:1798. https:\/\/doi.org\/10.3390\/biomedicines11071798","journal-title":"Biomedicines"},{"key":"12705_CR68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1248\/bpb.b23-00544","volume":"47","author":"B Sun","year":"2024","unstructured":"Sun B, Zhang L, Wu B, Luo X (2024) A Morpholine Derivative N-(4-Morpholinomethylene)ethanesulfonamide Induces Ferroptosis in Tumor Cells by Targeting NRF2. Biol Pharm Bull 47:417\u2013426. https:\/\/doi.org\/10.1248\/bpb.b23-00544","journal-title":"Biol Pharm Bull"},{"key":"12705_CR69","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41419-021-04306-2","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun Y, Berleth N, Wu W et al (2021) Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. Cell Death Dis 12:1028. https:\/\/doi.org\/10.1038\/s41419-021-04306-2","journal-title":"Cell Death Dis"},{"key":"12705_CR70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13048-024-01366-8","volume":"17","author":"N Li","year":"2024","unstructured":"Li N, Jiang X, Zhang Q et al (2024) Synergistic suppression of ovarian cancer by combining NRF2 and GPX4 inhibitors: in vitro and in vivo evidence. J Ovarian Res 17:49. https:\/\/doi.org\/10.1186\/s13048-024-01366-8","journal-title":"J Ovarian Res"},{"key":"12705_CR71","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.1007\/s00432-023-04811-1","volume":"149","author":"W Yue","year":"2023","unstructured":"Yue W, Yupeng G, Jun C, Kui J (2023) Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer. J Cancer Res Clin Oncol 149:8681\u20138689. https:\/\/doi.org\/10.1007\/s00432-023-04811-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"12705_CR72","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.bbrc.2020.05.069","volume":"530","author":"J Qiao","year":"2020","unstructured":"Qiao J, Chen Y, Mi Y et al (2020) NR5A2 synergizes with NCOA3 to induce breast cancer resistance to BET inhibitor by upregulating NRF2 to attenuate ferroptosis. Biochem Biophys Res Commun 530:402\u2013409. https:\/\/doi.org\/10.1016\/j.bbrc.2020.05.069","journal-title":"Biochem Biophys Res Commun"},{"key":"12705_CR73","doi-asserted-by":"publisher","first-page":"104650","DOI":"10.1016\/j.ebiom.2023.104650","volume":"93","author":"W Wu","year":"2023","unstructured":"Wu W, Zhao Y, Qin B et al (2023) Non-canonical role of UCKL1 on ferroptosis defence in colorectal cancer. EBioMedicine 93:104650. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104650","journal-title":"EBioMedicine"},{"key":"12705_CR74","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.chembiol.2021.01.006","volume":"28","author":"F Kuang","year":"2021","unstructured":"Kuang F, Liu J, Xie Y et al (2021) MGST1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells. Cell Chem Biol 28:765\u2013775e5. https:\/\/doi.org\/10.1016\/j.chembiol.2021.01.006","journal-title":"Cell Chem Biol"},{"key":"12705_CR75","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.chembiol.2023.04.007","volume":"30","author":"JM Hendricks","year":"2023","unstructured":"Hendricks JM, Doubravsky CE, Wehri E et al (2023) Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis. Cell Chem Biol 30:1090\u20131103e7. https:\/\/doi.org\/10.1016\/j.chembiol.2023.04.007","journal-title":"Cell Chem Biol"},{"key":"12705_CR76","volume-title":"Targeting NRF2 Driven Pathways in Cancer: Mechanisms of Resistance and Therapeutic Opportunities","author":"A Shakya","year":"2024","unstructured":"Shakya A (2024) Targeting NRF2 Driven Pathways in Cancer: Mechanisms of Resistance and Therapeutic Opportunities. The University of Arizona, Ph.D."},{"key":"12705_CR77","doi-asserted-by":"publisher","first-page":"116512","DOI":"10.1016\/j.biopha.2024.116512","volume":"174","author":"W Zhang","year":"2024","unstructured":"Zhang W, Liu Y, Liao Y et al (2024) GPX4, ferroptosis, and diseases. Biomed Pharmacother 174:116512. https:\/\/doi.org\/10.1016\/j.biopha.2024.116512","journal-title":"Biomed Pharmacother"},{"key":"12705_CR78","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z et al (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575:688\u2013692. https:\/\/doi.org\/10.1038\/s41586-019-1705-2","journal-title":"Nature"},{"key":"12705_CR79","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1038\/s41586-023-06269-0","volume":"619","author":"E Mishima","year":"2023","unstructured":"Mishima E, Nakamura T, Zheng J et al (2023) DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition. Nature 619:E9\u2013E18. https:\/\/doi.org\/10.1038\/s41586-023-06269-0","journal-title":"Nature"},{"key":"12705_CR80","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00031.2024","volume":"105","author":"J Zheng","year":"2025","unstructured":"Zheng J, Conrad M (2025) Ferroptosis: when metabolism meets cell death. Physiol Rev 105:651\u2013706. https:\/\/doi.org\/10.1152\/physrev.00031.2024","journal-title":"Physiol Rev"},{"key":"12705_CR81","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.molmed.2023.05.013","volume":"29","author":"W Li","year":"2023","unstructured":"Li W, Liang L, Liu S et al (2023) FSP1: a key regulator of ferroptosis. Trends Mol Med 29:753\u2013764. https:\/\/doi.org\/10.1016\/j.molmed.2023.05.013","journal-title":"Trends Mol Med"},{"key":"12705_CR82","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H et al (2017) Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 171:273\u2013285. https:\/\/doi.org\/10.1016\/j.cell.2017.09.021","journal-title":"Cell"},{"key":"12705_CR83","doi-asserted-by":"publisher","first-page":"108444","DOI":"10.1016\/j.celrep.2020.108444","volume":"33","author":"CA Wohlhieter","year":"2020","unstructured":"Wohlhieter CA, Richards AL, Uddin F et al (2020) Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Rep 33:108444. https:\/\/doi.org\/10.1016\/j.celrep.2020.108444","journal-title":"Cell Rep"},{"key":"12705_CR84","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/antiox13010070","volume":"13","author":"C Glorieux","year":"2024","unstructured":"Glorieux C, Enr\u00edquez C, Gonz\u00e1lez C et al (2024) The Multifaceted Roles of NRF2 in Cancer: Friend or Foe? Antioxid (Basel) 13:70. https:\/\/doi.org\/10.3390\/antiox13010070","journal-title":"Antioxid (Basel)"},{"key":"12705_CR85","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/cas.13537","volume":"109","author":"H Kitamura","year":"2018","unstructured":"Kitamura H, Motohashi H (2018) NRF2 addiction in cancer cells. Cancer Sci 109:900\u2013911. https:\/\/doi.org\/10.1111\/cas.13537","journal-title":"Cancer Sci"},{"key":"12705_CR86","doi-asserted-by":"publisher","first-page":"9095","DOI":"10.1158\/0008-5472.CAN-10-0384","volume":"70","author":"T Shibata","year":"2010","unstructured":"Shibata T, Saito S, Kokubu A et al (2010) Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. Cancer Res 70:9095\u20139105. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0384","journal-title":"Cancer Res"},{"key":"12705_CR87","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.bbrc.2017.04.133","volume":"487","author":"Y Xiang","year":"2017","unstructured":"Xiang Y, Ye W, Huang C et al (2017) Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK\/p38 MAPK\/NF-\u03bab\/Stat3\/Bcl-2 signaling pathway. Biochem Biophys Res Commun 487:820\u2013826. https:\/\/doi.org\/10.1016\/j.bbrc.2017.04.133","journal-title":"Biochem Biophys Res Commun"},{"key":"12705_CR88","doi-asserted-by":"publisher","first-page":"2360427","DOI":"10.1155\/2018\/2360427","volume":"2018","author":"Y Xiang","year":"2018","unstructured":"Xiang Y, Ye W, Huang C et al (2018) Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway. Oxid Med Cell Longev 2018:2360427. https:\/\/doi.org\/10.1155\/2018\/2360427","journal-title":"Oxid Med Cell Longev"},{"key":"12705_CR89","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12935-021-01822-1","volume":"21","author":"D Li","year":"2021","unstructured":"Li D, Hong X, Zhao F et al (2021) Targeting Nrf2 may reverse the drug resistance in ovarian cancer. Cancer Cell Int 21:116. https:\/\/doi.org\/10.1186\/s12935-021-01822-1","journal-title":"Cancer Cell Int"},{"key":"12705_CR90","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s12272-010-0511-z","volume":"33","author":"S Manandhar","year":"2010","unstructured":"Manandhar S, Lee S, Kwak MK (2010) Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells. Arch Pharm Res 33:717\u2013726. https:\/\/doi.org\/10.1007\/s12272-010-0511-z","journal-title":"Arch Pharm Res"},{"key":"12705_CR91","doi-asserted-by":"publisher","first-page":"8592348","DOI":"10.1155\/2019\/8592348","volume":"2019","author":"E Panieri","year":"2019","unstructured":"Panieri E, Saso L (2019) Potential Applications of NRF2 Inhibitors in Cancer Therapy. Oxid Med Cell Longev 2019:8592348. https:\/\/doi.org\/10.1155\/2019\/8592348","journal-title":"Oxid Med Cell Longev"},{"key":"12705_CR92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41420-024-01800-2","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, Wang Y, Tan J et al (2024) Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway. Cell Death Discov 10:35. https:\/\/doi.org\/10.1038\/s41420-024-01800-2","journal-title":"Cell Death Discov"},{"key":"12705_CR93","doi-asserted-by":"publisher","first-page":"e0177227","DOI":"10.1371\/journal.pone.0177227","volume":"12","author":"S Karathedath","year":"2017","unstructured":"Karathedath S, Rajamani BM, Musheer Aalam SM et al (2017) Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE 12:e0177227. https:\/\/doi.org\/10.1371\/journal.pone.0177227","journal-title":"PLoS ONE"},{"key":"12705_CR94","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.7150\/ijbs.82401","volume":"19","author":"J Zhang","year":"2023","unstructured":"Zhang J, Xu H-X, Zhu J-Q et al (2023) Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment. Int J Biol Sci 19:3029\u20133041. https:\/\/doi.org\/10.7150\/ijbs.82401","journal-title":"Int J Biol Sci"},{"key":"12705_CR95","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/QAI.0b013e3181fc0141","volume":"56","author":"HB Koon","year":"2011","unstructured":"Koon HB, Fingleton B, Lee JY et al (2011) Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 56:64\u201368. https:\/\/doi.org\/10.1097\/QAI.0b013e3181fc0141","journal-title":"J Acquir Immune Defic Syndr"},{"key":"12705_CR96","doi-asserted-by":"publisher","first-page":"110659","DOI":"10.1016\/j.jbc.2025.110659","volume":"301","author":"J Chembo","year":"2025","unstructured":"Chembo J, Bowman BM, Lapak K et al (2025) Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism. J Biol Chem 301:110659. https:\/\/doi.org\/10.1016\/j.jbc.2025.110659","journal-title":"J Biol Chem"},{"key":"12705_CR97","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/biology12050672","volume":"12","author":"F Aguayo","year":"2023","unstructured":"Aguayo F, Perez-Dominguez F, Osorio JC et al (2023) PI3K\/AKT\/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications. Biology (Basel) 12:672. https:\/\/doi.org\/10.3390\/biology12050672","journal-title":"Biology (Basel)"},{"key":"12705_CR98","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cllc.2020.10.006","volume":"22","author":"JW Riess","year":"2021","unstructured":"Riess JW, Frankel P, Shackelford D et al (2021) Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clin Lung Cancer 22:67\u201370. https:\/\/doi.org\/10.1016\/j.cllc.2020.10.006","journal-title":"Clin Lung Cancer"},{"key":"12705_CR99","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.esmoop.2025.104536","volume":"10","author":"MA Gouda","year":"2025","unstructured":"Gouda MA, Voss MH, Tawbi H et al (2025) A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open 10:104536. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104536","journal-title":"ESMO Open"},{"key":"12705_CR100","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1158\/2159-8290.CD-25-1187","volume":"16","author":"N Roy","year":"2026","unstructured":"Roy N, Wyseure T, Lo IC et al (2026) A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth. Cancer Discov 16:953\u2013975. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-1187","journal-title":"Cancer Discov"},{"key":"12705_CR101","doi-asserted-by":"publisher","first-page":"10824","DOI":"10.1074\/jbc.M116.722256","volume":"291","author":"SK Young","year":"2016","unstructured":"Young SK, Baird TD, Wek RC (2016) Translation Regulation of the Glutamyl-prolyl-tRNA Synthetase Gene EPRS through Bypass of Upstream Open Reading Frames with Noncanonical Initiation Codons. J Biol Chem 291:10824\u201310835. https:\/\/doi.org\/10.1074\/jbc.M116.722256","journal-title":"J Biol Chem"},{"key":"12705_CR102","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1751-2980.12870","volume":"21","author":"J Zhang","year":"2020","unstructured":"Zhang J, Han C, Lu WQ et al (2020) A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment. J Dig Dis 21:256\u2013263. https:\/\/doi.org\/10.1111\/1751-2980.12870","journal-title":"J Dig Dis"},{"key":"12705_CR103","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/ars.2017.7090","volume":"28","author":"X-X Fan","year":"2018","unstructured":"Fan XX, Leung ELH, Xie Y et al (2018) Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases. Antioxid Redox Signal 28:339\u2013357. https:\/\/doi.org\/10.1089\/ars.2017.7090","journal-title":"Antioxid Redox Signal"},{"key":"12705_CR104","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","volume":"5","author":"Y-X Chen","year":"2020","unstructured":"Chen YX, Gao QY, Zou TH et al (2020) Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol 5:267\u2013275. https:\/\/doi.org\/10.1016\/S2468-1253(19)30409-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12705_CR105","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1097\/CM9.0000000000002752","volume":"136","author":"Y Qian","year":"2023","unstructured":"Qian Y, Kang Z, Zhao L et al (2023) Berberine might block colorectal carcinogenesis by inhibiting the regulation of B-cell function by Veillonella parvula. Chin Med J (Engl) 136:2722\u20132731. https:\/\/doi.org\/10.1097\/CM9.0000000000002752","journal-title":"Chin Med J (Engl)"},{"key":"12705_CR106","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1158\/1940-6207.CAPR-24-0386","volume":"18","author":"J-M Yuan","year":"2025","unstructured":"Yuan JM, Kensler TW, Dacic S et al (2025) Randomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer. Cancer Prev Res (Phila) 18:335\u2013345. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-24-0386","journal-title":"Cancer Prev Res (Phila)"},{"key":"12705_CR107","doi-asserted-by":"publisher","first-page":"e088924","DOI":"10.1136\/bmjopen-2024-088924","volume":"15","author":"A Jia","year":"2025","unstructured":"Jia A, Kuramoto L, Khakban A et al (2025) Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol. BMJ Open 15:e088924. https:\/\/doi.org\/10.1136\/bmjopen-2024-088924","journal-title":"BMJ Open"},{"key":"12705_CR108","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1182\/blood.2022018669","volume":"142","author":"JP Nicolay","year":"2023","unstructured":"Nicolay JP, Melchers S, Albrecht JD et al (2023) Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study. Blood 142:794\u2013805. https:\/\/doi.org\/10.1182\/blood.2022018669","journal-title":"Blood"},{"key":"12705_CR109","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.21873\/anticanres.11551","volume":"37","author":"PP Sordillo","year":"2017","unstructured":"Sordillo PP, Sordillo LA, Helson L (2017) The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma. Anticancer Res 37:2159\u20132171. https:\/\/doi.org\/10.21873\/anticanres.11551","journal-title":"Anticancer Res"},{"key":"12705_CR110","doi-asserted-by":"crossref","unstructured":"Sordillo PP, Sordillo LA (2021) Glioblastoma cell-induced immunosuppression causing chemoresistance. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies.Edited by Ramasamy Paulmurugan and Tarik F. Massoud Elsevier, pp 293\u2013317","DOI":"10.1016\/B978-0-12-821567-8.00008-7"},{"key":"12705_CR111","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/1940-6207.CAPR-25-0363","volume":"19","author":"M Gonzalez-Pons","year":"2026","unstructured":"Gonzalez-Pons M, Dominguez RL, Montalvan-Sanchez EE et al (2026) Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis. Cancer Prev Res (Phila) 19:403\u2013413. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-25-0363","journal-title":"Cancer Prev Res (Phila)"},{"key":"12705_CR112","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1940-6207.CAPR-23-0345","volume":"17","author":"EE Montalvan-Sanchez","year":"2024","unstructured":"Montalvan-Sanchez EE, Hernandez-Marrero J, Norwood DA et al (2024) Establishment of a Mesoamerican-Caribbean South-South Research Platform: Challenges in the Meriva (Curcuminoids) Gastric Cancer Chemoprevention Trial. Cancer Prev Res (Phila) 17:549\u2013555. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-23-0345","journal-title":"Cancer Prev Res (Phila)"},{"key":"12705_CR113","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jn\/nxz029","volume":"149","author":"LM Howells","year":"2019","unstructured":"Howells LM, Iwuji COO, Irving GRB et al (2019) Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. J Nutr 149:1133\u20131139. https:\/\/doi.org\/10.1093\/jn\/nxz029","journal-title":"J Nutr"},{"key":"12705_CR114","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.canlet.2015.05.005","volume":"364","author":"MI James","year":"2015","unstructured":"James MI, Iwuji C, Irving G et al (2015) Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett 364:135\u2013141. https:\/\/doi.org\/10.1016\/j.canlet.2015.05.005","journal-title":"Cancer Lett"},{"key":"12705_CR115","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13063-015-0641-1","volume":"16","author":"GR Irving","year":"2015","unstructured":"Irving GR, Iwuji CO, Morgan B et al (2015) Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. Trials 16:110. https:\/\/doi.org\/10.1186\/s13063-015-0641-1","journal-title":"Trials"},{"key":"12705_CR116","doi-asserted-by":"publisher","first-page":"153473542514101","DOI":"10.1177\/15347354251410182","volume":"25","author":"JU Heo","year":"2026","unstructured":"Heo JU, Rao S, Newton HB et al (2026) Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [18F]FDG PET\/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials. Integr Cancer Ther 25:15347354251410182. https:\/\/doi.org\/10.1177\/15347354251410182","journal-title":"Integr Cancer Ther"},{"key":"12705_CR117","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11523-021-00855-w","volume":"17","author":"T Shimizu","year":"2022","unstructured":"Shimizu T, Kuboki Y, Lin C-C et al (2022) A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Target Oncol 17:15\u201324. https:\/\/doi.org\/10.1007\/s11523-021-00855-w","journal-title":"Target Oncol"},{"key":"12705_CR118","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1158\/1541-7786.MCR-18-0923","volume":"17","author":"A Hern\u00e1ndez-Prat","year":"2019","unstructured":"Hern\u00e1ndez-Prat A, Rodriguez-Vida A, Juanpere-Rodero N et al (2019) Novel Oral mTORC1\/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3K\u03b1 Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Mol Cancer Res 17:1931\u20131944. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0923","journal-title":"Mol Cancer Res"},{"key":"12705_CR119","doi-asserted-by":"publisher","first-page":"102123","DOI":"10.1016\/j.clgc.2024.102123","volume":"22","author":"J Bellmunt","year":"2024","unstructured":"Bellmunt J, Maroto P, Bonfill T et al (2024) Dual mTOR1\/2 Inhibitor Sapanisertib (FTH-003\/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. Clin Genitourin Cancer 22:102123. https:\/\/doi.org\/10.1016\/j.clgc.2024.102123","journal-title":"Clin Genitourin Cancer"},{"key":"12705_CR120","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13063-021-05669-9","volume":"23","author":"CN de la Rosa","year":"2022","unstructured":"de la Rosa CN, Krell J, Day E et al (2022) Statistical analysis plan for the Dual mTorc Inhibition in advanCed\/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE). Trials 23:13. https:\/\/doi.org\/10.1186\/s13063-021-05669-9","journal-title":"Trials"},{"key":"12705_CR121","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13063-022-06201-3","volume":"23","author":"F Fiorentino","year":"2022","unstructured":"Fiorentino F, Krell J, de la Rosa CN, Webber L (2022) DICE: Dual mTorc Inhibition in advanCed\/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228. Trials 23:261. https:\/\/doi.org\/10.1186\/s13063-022-06201-3","journal-title":"Trials"},{"key":"12705_CR122","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s43018-023-00647-3","volume":"5","author":"J Encarnaci\u00f3n-Rosado","year":"2024","unstructured":"Encarnaci\u00f3n-Rosado J, Sohn ASW, Biancur DE et al (2024) Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nat Cancer 5:85\u201399. https:\/\/doi.org\/10.1038\/s43018-023-00647-3","journal-title":"Nat Cancer"},{"key":"12705_CR123","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12885-023-11797-z","volume":"24","author":"M Mastall","year":"2024","unstructured":"Mastall M, Roth P, Bink A et al (2024) A phase Ib\/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC Cancer 24:82. https:\/\/doi.org\/10.1186\/s12885-023-11797-z","journal-title":"BMC Cancer"},{"key":"12705_CR124","doi-asserted-by":"publisher","first-page":"104241","DOI":"10.1016\/j.redox.2026.104241","volume":"95","author":"BS Skeie","year":"2026","unstructured":"Skeie BS, Craig-Craven AR, Gr\u00fcner ER et al (2026) Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma. Redox Biol 95:104241. https:\/\/doi.org\/10.1016\/j.redox.2026.104241","journal-title":"Redox Biol"},{"key":"12705_CR125","doi-asserted-by":"publisher","first-page":"215649","DOI":"10.1016\/j.canlet.2022.215649","volume":"535","author":"F Wang","year":"2022","unstructured":"Wang F, Oudaert I, Tu C et al (2022) System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance. Cancer Lett 535:215649. https:\/\/doi.org\/10.1016\/j.canlet.2022.215649","journal-title":"Cancer Lett"},{"key":"12705_CR126","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ymthe.2021.03.013","volume":"29","author":"N Liu","year":"2021","unstructured":"Liu N, Zhang J, Yin M et al (2021) Inhibition of xCT suppresses the efficacy of anti-PD-1\/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol Ther 29:2321\u20132334. https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.013","journal-title":"Mol Ther"},{"key":"12705_CR127","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y et al (2021) Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol 22:977\u2013990. https:\/\/doi.org\/10.1016\/S1470-2045(21)00252-7","journal-title":"Lancet Oncol"},{"key":"12705_CR128","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00280-018-3533-8","volume":"81","author":"JF Deeken","year":"2018","unstructured":"Deeken JF, Wang H, Hartley M et al (2018) A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 81:587\u2013596. https:\/\/doi.org\/10.1007\/s00280-018-3533-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"12705_CR129","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-017-4261-1","volume":"164","author":"C von Hagens","year":"2017","unstructured":"von Hagens C, Walter-Sack I, Goeckenjan M et al (2017) Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33\/2). Breast Cancer Res Treat 164:359\u2013369. https:\/\/doi.org\/10.1007\/s10549-017-4261-1","journal-title":"Breast Cancer Res Treat"},{"key":"12705_CR130","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00280-016-2960-7","volume":"77","author":"M K\u00f6nig","year":"2016","unstructured":"K\u00f6nig M, von Hagens C, Hoth S et al (2016) Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother Pharmacol 77:413\u2013427. https:\/\/doi.org\/10.1007\/s00280-016-2960-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"12705_CR131","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00228-014-1754-2","volume":"70","author":"T Ericsson","year":"2014","unstructured":"Ericsson T, Blank A, von Hagens C et al (2014) Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol 70:1453\u20131463. https:\/\/doi.org\/10.1007\/s00228-014-1754-2","journal-title":"Eur J Clin Pharmacol"},{"key":"12705_CR132","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA (2024) The cell biology of ferroptosis. Nat Rev Mol Cell Biol 25:424\u2013442. https:\/\/doi.org\/10.1038\/s41580-024-00703-5","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12705_CR133","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru Q, Li Y, Chen L et al (2024) Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Sig Transduct Target Ther 9:271. https:\/\/doi.org\/10.1038\/s41392-024-01969-z","journal-title":"Sig Transduct Target Ther"},{"key":"12705_CR134","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.123","author":"D Tang","year":"2024","unstructured":"Tang D, Kang R (2024) NFE2L2 and ferroptosis resistance in cancer therapy. Cancer Drug Resist. https:\/\/doi.org\/10.20517\/cdr.2024.123","journal-title":"Cancer Drug Resist"},{"key":"12705_CR135","doi-asserted-by":"publisher","first-page":"101296","DOI":"10.1016\/j.drup.2025.101296","volume":"83","author":"S Wang","year":"2025","unstructured":"Wang S, Zhang C, Zhou S et al (2025) RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma. Drug Resist Updates 83:101296. https:\/\/doi.org\/10.1016\/j.drup.2025.101296","journal-title":"Drug Resist Updates"},{"key":"12705_CR136","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.4155\/fmc-2023-0125","volume":"15","author":"G Gupta","year":"2023","unstructured":"Gupta G, Bhat AA, Goyal A et al (2023) Exploring ACSL4\/LPCAT3\/ALOX15 and SLC7A11\/GPX4\/NFE2L2 as Potential Targets in Ferroptosis-Based Cancer Therapy. Future Med Chem 15:1209\u20131212. https:\/\/doi.org\/10.4155\/fmc-2023-0125","journal-title":"Future Med Chem"},{"key":"12705_CR137","doi-asserted-by":"publisher","first-page":"121131","DOI":"10.1016\/j.cca.2026.121131","volume":"591","author":"AG Taki","year":"2026","unstructured":"Taki AG, Shareef A, Arora V et al (2026) Ferroptosis in cancer: integrating multi-omics, AI-driven biomarkers, and translational challenges. Clin Chim Acta 591:121131. https:\/\/doi.org\/10.1016\/j.cca.2026.121131","journal-title":"Clin Chim Acta"},{"key":"12705_CR138","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-09-3352","volume":"16","author":"LM Solis","year":"2010","unstructured":"Solis LM, Behrens C, Dong W et al (2010) Nrf2 and Keap1 Abnormalities in Non\u2013Small Cell Lung Carcinoma and Association with Clinicopathologic Features. Clin Cancer Res 16:3743\u20133753. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3352","journal-title":"Clin Cancer Res"},{"key":"12705_CR139","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/mco2.70010","volume":"5","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Le J et al (2024) Ferroptosis: mechanisms and therapeutic targets. MedComm 5:e70010. https:\/\/doi.org\/10.1002\/mco2.70010","journal-title":"MedComm"},{"key":"12705_CR140","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1080\/21655979.2021.2017627","volume":"13","author":"S Du","year":"2022","unstructured":"Du S, Zeng F, Sun H et al (2022) Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients. Bioengineered 13:2498\u20132512. https:\/\/doi.org\/10.1080\/21655979.2021.2017627","journal-title":"Bioengineered"},{"key":"12705_CR141","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/0113892037315874240826112422","volume":"26","author":"Z Xie","year":"2025","unstructured":"Xie Z, Hou Q, He Y et al (2025) Ferritin Hinders Ferroptosis in Non-Tumorous Diseases: Regulatory Mechanisms and Potential Consequences. CPPS 26:89\u2013104. https:\/\/doi.org\/10.2174\/0113892037315874240826112422","journal-title":"CPPS"},{"key":"12705_CR142","doi-asserted-by":"publisher","first-page":"115807","DOI":"10.1016\/j.celrep.2025.115807","volume":"44","author":"A \u010ca\u010dkovi\u0107","year":"2025","unstructured":"\u010ca\u010dkovi\u0107 A, Pjevac P, Orli\u0107 S, Reintjes G (2025) Selective heterotrophic bacteria can selfishly process polysaccharides in freshwater lakes. Cell Rep 44:115807. https:\/\/doi.org\/10.1016\/j.celrep.2025.115807","journal-title":"Cell Rep"},{"key":"12705_CR143","doi-asserted-by":"publisher","first-page":"108785","DOI":"10.1016\/j.biotechadv.2025.108785","volume":"87","author":"H Chen","year":"2026","unstructured":"Chen H, Shi Y, Yuan M et al (2026) Integrating multi-omics and artificial intelligence fuels advanced target identification and drug discovery. Biotechnol Adv 87:108785. https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108785","journal-title":"Biotechnol Adv"},{"key":"12705_CR144","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.tips.2023.06.005","volume":"44","author":"R Kim","year":"2023","unstructured":"Kim R, Taylor D, Vonderheide RH, Gabrilovich DI (2023) Ferroptosis of immune cells in the tumor microenvironment. Trends Pharmacol Sci 44:542\u2013552. https:\/\/doi.org\/10.1016\/j.tips.2023.06.005","journal-title":"Trends Pharmacol Sci"},{"key":"12705_CR145","doi-asserted-by":"publisher","first-page":"111328","DOI":"10.1016\/j.cellsig.2024.111328","volume":"122","author":"X-Q Liu","year":"2024","unstructured":"Liu XQ, Shi MZ, Bai YT et al (2024) Hypoxia and ferroptosis. Cell Signal 122:111328. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111328","journal-title":"Cell Signal"},{"key":"12705_CR146","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE et al (2019) CD8\u2009+\u2009T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569:270\u2013274. https:\/\/doi.org\/10.1038\/s41586-019-1170-y","journal-title":"Nature"},{"key":"12705_CR147","doi-asserted-by":"publisher","first-page":"15328","DOI":"10.1021\/acsnano.3c04632","volume":"17","author":"H Yang","year":"2023","unstructured":"Yang H, Yao X, Liu Y et al (2023) Ferroptosis Nanomedicine: Clinical Challenges and Opportunities for Modulating Tumor Metabolic and Immunological Landscape. ACS Nano 17:15328\u201315353. https:\/\/doi.org\/10.1021\/acsnano.3c04632","journal-title":"ACS Nano"},{"key":"12705_CR148","doi-asserted-by":"publisher","first-page":"100960","DOI":"10.1016\/j.jpha.2024.03.001","volume":"14","author":"M Zhang","year":"2024","unstructured":"Zhang M, Guo M, Gao Y et al (2024) Mechanisms and therapeutic targets of ferroptosis: Implications for nanomedicine design. J Pharm Anal 14:100960. https:\/\/doi.org\/10.1016\/j.jpha.2024.03.001","journal-title":"J Pharm Anal"},{"key":"12705_CR149","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1039\/d3tb02308g","volume":"12","author":"Y Li","year":"2024","unstructured":"Li Y, Wei C, Yan J et al (2024) The application of nanoparticles based on ferroptosis in cancer therapy. J Mater Chem B 12:413\u2013435. https:\/\/doi.org\/10.1039\/d3tb02308g","journal-title":"J Mater Chem B"},{"key":"12705_CR150","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12951-024-02842-5","volume":"22","author":"S Han","year":"2024","unstructured":"Han S, Zou J, Xiao F et al (2024) Nanobiotechnology boosts ferroptosis: opportunities and challenges. J Nanobiotechnol 22:606. https:\/\/doi.org\/10.1186\/s12951-024-02842-5","journal-title":"J Nanobiotechnol"},{"key":"12705_CR151","doi-asserted-by":"publisher","first-page":"111004","DOI":"10.1016\/j.cbi.2024.111004","volume":"395","author":"M-S Hsieh","year":"2024","unstructured":"Hsieh M-S, Ling HH, Setiawan SA et al (2024) Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer. Chemico-Biol Interact 395:111004. https:\/\/doi.org\/10.1016\/j.cbi.2024.111004","journal-title":"Chemico-Biol Interact"},{"key":"12705_CR152","doi-asserted-by":"publisher","first-page":"e013269","DOI":"10.1136\/jitc-2025-013269","volume":"13","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yu R, Li Q et al (2025) Epigenetic suppression of Nrf2\u2013Slc40a1 axis induces ferroptosis and enhances immunotherapy in pancreatic cancer. J Immunother Cancer 13:e013269. https:\/\/doi.org\/10.1136\/jitc-2025-013269","journal-title":"J Immunother Cancer"},{"key":"12705_CR153","doi-asserted-by":"publisher","unstructured":"Cai R, Zhan W, Lyu X et al (2026) PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer. https:\/\/doi.org\/10.1136\/gutjnl-2026-338195. Gut gutjnl-2026-338195","DOI":"10.1136\/gutjnl-2026-338195"},{"key":"12705_CR154","doi-asserted-by":"publisher","first-page":"1558814","DOI":"10.3389\/fimmu.2025.1558814","volume":"16","author":"J Luo","year":"2025","unstructured":"Luo J, Zhi Q, Li D et al (2025) Low dose radiotherapy combined with immune checkpoint inhibitors induces ferroptosis in lung cancer via the Nrf2\/HO-1\/GPX4 axis. Front Immunol 16:1558814. https:\/\/doi.org\/10.3389\/fimmu.2025.1558814","journal-title":"Front Immunol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12705-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12705-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12705-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:21:33Z","timestamp":1788596493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12705-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":154,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12705"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12705-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to publish.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1528"}}